Biolingus is a Swiss biotech company spearheading the development of oral (sublingual) and mucosal delivery of peptides and proteins. Our technology is derived from applied bio-engineering, resulting in novel bio-mimetic materials. It is a cutting-edge and mature solution for oral formulations not only for peptides but also proteins, novelprotein scaffolds, vaccines, immunotherapies, enzymes and also very hydrophobic small molecules. The company focuses the development of its own products on treatment of chronic diseases, such as diabetes and inflammatory diseases. In addition to that, a particular area of interest is oral immunotherapy, as our technology has shown an outstanding performance in this area.